论文部分内容阅读
目的:观察多西他赛联合替吉奥治疗蒽环类耐药晚期乳腺癌的疗效及不良反应。方法:多西他赛75 mg·m~(-2),第1天;替吉奥40 mg·m~(-2)餐后口服,bid,连用14 d,21 d为1周期,每结束2周期评价疗效及不良反应。结果:40例蒽环类耐药晚期乳腺癌患者总有效率57.5%,肿瘤控制率80%,中位生存期420 d,中位疾病进展时间221 d,1年生存率67.5%。主要不良反应为骨髓抑制,其次为手足综合征、恶心、呕吐、腹泻、纳差等不良反应,经对症处理均可耐受,无治疗相关死亡患者。结论:多西他赛联合替吉奥治疗蒽环类耐药乳腺癌的疗效好,不良反应可耐受,值得临床推广使用。
Objective: To observe the efficacy and adverse reactions of docetaxel combined with tiagre in the treatment of advanced anthracycline-resistant breast cancer. Methods: Docetaxel 75 mg · m ~ (-2) on the first day; for the 40 mg · m ~ (-2) meal after the meal, bid, for 14 days, 21 days for 1 cycle, each end 2 cycles to evaluate the efficacy and adverse reactions. Results: The total effective rate was 57.5%, the tumor control rate was 40%, the median survival time was 420 days, the median disease progression time was 221 days, and the 1-year survival rate was 67.5% in 40 patients with advanced anthracycline-resistant breast cancer. The main adverse reactions were myelosuppression, followed by hand-foot syndrome, nausea, vomiting, diarrhea, anorexia and other adverse reactions, can be tolerated by symptomatic treatment, no treatment-related deaths. Conclusion: Docetaxel combined with tirofiban can effectively treat anthracycline-resistant breast cancer. Adverse reactions are tolerable and worthy of clinical application.